Patent intelligence · US
US 8646461
Device and method for simulating chemosensation of smoking
Device and method for simulating chemosensation of smoking
Patent details — US 8646461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 11, 2014
- Expiration
- Feb 6, 2034
- Applicant
- Sentiens, LLC
- Claims
- 26
- CPC classes
- A61P, A61P25/34, A61P43/00
Quick answer
US 8646461 (Device and method for simulating chemosensation of smoking) is held by Sentiens, LLC. Status: granted. Granted Feb 11, 2014. Expires Feb 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sentiens, LLC
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61P, A61P25/34, A61P43/00
More from Sentiens, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 8646461?
US 8646461 (Device and method for simulating chemosensation of smoking) is held by Sentiens, LLC. Status: granted. Granted Feb 11, 2014. Expires Feb 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8646461?
Sentiens, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 8646461 expire?
Our index shows an expiration date of Feb 6, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.